DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model

(2013) A. Sevko et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells Interact with Tumors in Terms of Myelopoiesis, Tumorigenesis and Immunosuppression: Thick as Thieves

(2013) Alexandra Sevko et al.   Journal of Cancer

Immune effects of 5-fluorouracil

(2013) François Ghiringhelli et al.   OncoImmunology

Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice

(2012) Pierre L. Triozzi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cyclophosphamide-induced Myeloid-derived Suppressor Cell Population Is Immunosuppressive But Not Identical to Myeloid-derived Suppressor Cells Induced By Growing TC-1 Tumors

(2012) Romana Mikyšková et al.   JOURNAL OF IMMUNOTHERAPY

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner

(2012) Tillmann Michels et al.   Journal of Immunotoxicology

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

(2011) J Šímová et al.   BRITISH JOURNAL OF CANCER

Generation of antitumor response by IL-2-transduced JAWS II dendritic cells

(2011) Joanna Rossowska et al.   IMMUNOBIOLOGY

Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo

(2011) Brian R. Rosborough et al.   JOURNAL OF LEUKOCYTE BIOLOGY

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Immunotherapy of MHC class I-deficient tumors

(2010) Milan Reiniš   Future Oncology

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting

(2009) L. I. Sanchez-Abarca et al.   BLOOD

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine

(2009) Irina Daurkin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Therapeutic targeting of myeloid-derived suppressor cells

(2009) Stefano Ugel et al.   CURRENT OPINION IN PHARMACOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY